Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 5/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18334499 | 0.87 | GAA (0.33) | GAAALDH1A1LMNAELANEMTNR1A | |
| SCHEMBL18334565 | 0.87 | GAA (0.33) | GAAALDH1A1LMNAELANEMTNR1A | |
| SCHEMBL18334469 | 0.87 | GAA (0.33) | GAAALDH1A1LMNAELANEMTNR1A | |
| SCHEMBL18334510 | 0.76 | GAA (0.32) | GAAALDH1A1KDM4EELANE | |
| SCHEMBL18334461 | 0.75 | MTNR1A (0.40) | GAAALDH1A1LMNAMTNR1AMTNR1B | |
| SCHEMBL18334436 | 0.73 | KDM4E (0.34) | GAAALDH1A1KDM4ELMNAELANE | |
| SCHEMBL18334587 | 0.72 | ESR1 (0.41) | GAAALDH1A1LMNAELANE | |
| SCHEMBL18334440 | 0.71 | CHRM2 (0.34) | ELANE | |
| SCHEMBL18334505 | 0.71 | CHRM2 (0.32) | LMNAELANE | |
| SCHEMBL18015895 | 0.69 | LMNA (0.36) | GAAALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| EP-3109239-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-12-28 | — | — | EP | disclosed |
| CN-105980363-A | Aminopyrazolone Derivatives | 第三共株式会社 | 2016-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | ATAD5, ATP1A1, TIPRL | GAA 2530/4885ALDH1A1 2821/4885KDM4E 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.